Trader Eugene: Bitcoin Remains a Key Allocation in This Week's Crypto Portfolio
Odaily Planet Daily News: Trader Eugene stated in his community that in this cycle, if a portfolio lacks a core allocation of Bitcoin, its risk-adjusted returns generally underperform traditional stock market indices (such as the S&P 500). Compared to the 2019–2022 cycle, where crypto assets significantly outperformed traditional assets, in this cycle, the compound growth of indicators like ETH, SOL, and TOTAL3 (the total market cap excluding BTC and ETH) has not surpassed the US stock benchmarks.
He believes that as the crypto market matures and public allocation ratios increase, the era of "achieving financial freedom through crypto assets" is fading. If one continues to hold only crypto assets in the future without allocating BTC or leveraging BTC, it may become a strategic mistake. Even in cycles with increased risk appetite, a 2x long position in BTC may outperform a single long position in other high-beta cryptocurrencies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
